Koninklijke DSM (OTCMKTS:RDSMY – Get Rating) had its price objective trimmed by Barclays from €189.00 ($201.06) to €188.00 ($200.00) in a research report released on Wednesday morning, The Fly reports.
RDSMY has been the topic of a number of other research reports. Zacks Investment Research upgraded shares of Koninklijke DSM from a sell rating to a hold rating in a report on Tuesday, February 15th. UBS Group cut their price target on shares of Koninklijke DSM from €190.00 ($202.13) to €185.00 ($196.81) and set a buy rating on the stock in a report on Thursday, March 31st. Societe Generale upgraded shares of Koninklijke DSM from a hold rating to a buy rating in a report on Wednesday, February 23rd. Credit Suisse Group cut their price target on shares of Koninklijke DSM from €205.00 ($218.09) to €182.00 ($193.62) and set an outperform rating on the stock in a report on Thursday, February 17th. Finally, Morgan Stanley cut their price target on shares of Koninklijke DSM from €166.00 ($176.60) to €155.00 ($164.89) and set an equal weight rating on the stock in a report on Monday, March 28th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of Buy and an average target price of $177.50.
Shares of RDSMY opened at $38.15 on Wednesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.58 and a current ratio of 2.52. Koninklijke DSM has a fifty-two week low of $35.36 and a fifty-two week high of $56.92. The firm’s 50-day simple moving average is $41.08 and its two-hundred day simple moving average is $47.12.
Koninklijke DSM Company Profile (Get Rating)
Koninklijke DSM N.V., a science-based company, engages in nutrition, health, and sustainable living businesses in the Netherlands, Switzerland, rest of Europe, North America, Latin America, China, rest of Asia, and internationally. It operates through Nutrition, Materials, and Innovation Center segments.
- Get a free copy of the StockNews.com research report on Koninklijke DSM (RDSMY)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
Receive News & Ratings for Koninklijke DSM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke DSM and related companies with MarketBeat.com's FREE daily email newsletter.